FierceBiotech· @FierceBiotech · X·· 1 小时前精选AI 评分72
AI 导读
辉瑞与中国Starna Therapeutics达成最高26亿美元的交易,引进三项临床前自身免疫疾病项目,进入体内CAR-T领域,其中包括3.3亿美元首付款。交易标的均处于临床前阶段。
推荐理由
交易金额与首付款结构显示跨国药企通过授权引进切入体内CAR-T这一早期技术方向。
正文
Pfizer is entering the in vivo CAR-T race with a deal worth up to $2.6 billion for three preclinical autoimmune programs from China’s Starna Therapeutics, including $330 million upfront. https://www.fiercebiotech.com/biotech/pfizer-enters-vivo-car-t-space-3-program-26b-deal-chinas-starna
来源:FierceBiotech · x.com